Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study

Ribociclib Delays QOL Deterioration While Extending Survival

Contrary to the toxicity-tradeoff paradox, adding Ribociclib to Fulvestrant maintains Quality of Life and delays pain deterioration by ~7 months.

Design · Phase III Randomized Clinical Trial (MONALEESA-3) N · 726 Population · Postmenopausal HR+/HER2- Advanced Breast Cancer (1st or 2nd line) Duration · Median follow-up 20.4 months Arms · Ribociclib + Fulvestrant vs. Placebo + Fulvestrant Double-blind Placebo-controlled 2:1 Randomization

Key Performance Indicators

PRIMARY
Global Health Deterioration HR
0.81
95% CI: 0.62–1.1
19% risk reduction (trend)
Pain Severity Deterioration HR
0.77
95% CI: 0.57–1.05
23% risk reduction (trend)
Median TTD (Pain BPI)
+6.8 mo
42.7 vs 35.9 months
Extended pain control
1

Risk of Deterioration Across QOL Domains (Hazard Ratios)

Hazard Ratios < 1.0 indicate a favorable delay in deterioration for the Ribociclib arm. While some CIs cross 1.0, the consistent leftward shift suggests a systemic benefit in delaying symptom worsening.

2

Median Time to Deterioration (Months)

Patients on Ribociclib experienced a longer duration before their Quality of Life or Pain scores deteriorated by ≥10%. The gap represents the 'time gained' in a stable health state.

3

Symptom Stability: Baseline vs. Cycle 15

Despite the addition of a CDK4/6 inhibitor, symptom scores (0-100 scale) remained remarkably stable after >1 year of treatment. Higher scores = better for GHS; higher = worse for Pain/Fatigue.

4

Early Pain Reduction (Week 8)

Change from baseline in EORTC QLQ-C30 pain scores at 8 weeks. Both groups showed reduction, with Ribociclib showing a numerically larger (though statistically similar) reduction.

Editorial Conclusion

“Ribociclib + Fulvestrant breaks the typical efficacy-toxicity tradeoff by significantly extending progression-free survival while simultaneously delaying the deterioration of quality of life and pain.”
Median time to ≥10% deterioration in pain was extended by 6.8 months (42.7 vs 35.9) in the Ribociclib arm.
Global Health Status deterioration risk was reduced by 19% (HR 0.81), driven by the delay in disease progression.
Symptom scores at Cycle 15 were comparable to baseline, confirming the regimen's long-term tolerability.
Clinical Implication
Clinicians can prescribe this combination with confidence that the survival benefits do not come at the cost of the patient's daily functioning or increased pain burden.

Reference Data & Sources

Complete Data Table

Metric Group Value Unit Source
TTD Global Health Status (≥10%)Ribociclib vs Placebo0.81 (0.62–1.1)HRAbstract/Results
TTD Pain Severity Index (BPI-SF)Ribociclib vs Placebo0.77 (0.57–1.05)HRResults
Median TTD Physical FunctioningRibociclib38.7monthsResults
Median TTD Physical FunctioningPlacebo34.9monthsResults

Abbreviations

HR = Hazard Ratio · CI = Confidence Interval · TTD = Time to Definitive Deterioration · GHS = Global Health Status · BPI-SF = Brief Pain Inventory-Short Form

Source

Fasching et al. The Breast 54 (2020) 148-154
DOI: 10.1016/j.breast.2020.09.008

Limitations

No post-progression PRO assessments were collected. Differences in TTD were numerically favorable but not all statistically significant (CIs crossed 1).
Selected: none

AI edit element

Describe the change you want. Optional: attach an image.
No image attached

Theme

👀 View Mode